Utility of endoscopic ultrasound for assessment of locoregional recurrence of pancreatic adenocarcinoma after surgical resection.
Jonathan G RaghebC Roberto Simons-LinaresChristopher PluskotaBradley ConferRobert ButlerDavid L DiehlHarshit S KharaAmitpal S JohalR Matthew WalshPrabhleen ChahalPublished in: Endoscopy international open (2023)
Background and study aims Up to 80 % of patients with pancreatic adenocarcinoma develop locoregional recurrence after primary resection. However, the detection of recurrent pancreatic ductal adenocarcinoma (RPDAC) after pancreatic surgery can be challenging because of difficulty distinguishing locoregional recurrence from normal postoperative or post-radiation changes. We sought to evaluate the utility of endoscopic ultrasound (EUS), in detecting pancreatic adenocarcinoma recurrence after surgical resection and its impact on the clinical management of patients. Patients and methods This was a retrospective study of all pancreatic cancer patients who underwent EUS post-resection at two tertiary care centers between January 2004 and June 2019. Results Sixty-seven patients were identified. Of these, 57 (85 %) were diagnosed with RPDAC, resulting in change in clinical management of 46 (72 %) patients. EUS identified masses not seen on computed tomography, magnetic resonance imaging, or positron emission tomography in seven (14 %). Conclusions EUS is useful in detecting RPDAC after pancreatic surgery and can lead to significant impact on clinical management.
Keyphrases
- computed tomography
- magnetic resonance imaging
- positron emission tomography
- end stage renal disease
- ultrasound guided
- fine needle aspiration
- minimally invasive
- chronic kidney disease
- ejection fraction
- newly diagnosed
- tertiary care
- prognostic factors
- peritoneal dialysis
- pet ct
- contrast enhanced
- acute coronary syndrome
- label free
- free survival
- contrast enhanced ultrasound